← Back to Search

Tasimelteon for Delayed Sleep-Wake Phase Disorder

Phase 3
Recruiting
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

This trial tests a pill called tasimelteon in people who have trouble falling asleep and waking up at normal times. The goal is to see if tasimelteon can help reset their sleep schedule. Both men and women with this sleep disorder are included in the study.

Who is the study for?
This trial is for men and women aged 18-75 with a confirmed diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD). Participants must have a BMI between 18 and 35, be able to consent, and not have had psychiatric disorders in the past year. Pregnant or breastfeeding women, recent surgery patients, or those who've been immobile for extended periods cannot join.
What is being tested?
The study compares the effects of Tasimelteon—a medication—against a placebo in treating DSWPD. It's conducted across multiple centers where participants are randomly assigned to receive either Tasimelteon or an inactive pill without knowing which one they're getting.
What are the potential side effects?
While specific side effects aren't listed here, clinical trials like this often monitor for any adverse reactions ranging from mild discomforts such as headaches or nausea to more serious conditions that could affect sleep patterns, mood, or physical health.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2018 Phase 3 trial • 320 Patients • NCT03373201
5%
Headache
1%
Atrial Fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Tasimelteon

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TasimelteonExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tasimelteon
2016
Completed Phase 3
~540

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Chronobiology Disorders, such as melatonin receptor agonists (e.g., Tasimelteon) and melatonin supplementation, work by targeting the body's circadian rhythm. Melatonin receptor agonists bind to melatonin receptors in the brain, mimicking the natural hormone's effects to help regulate sleep-wake cycles. Melatonin supplements increase the levels of melatonin in the body, promoting sleep onset and adjusting the circadian phase. Light therapy, another common treatment, involves exposure to bright light at specific times to shift the circadian rhythm. These treatments are crucial for patients with Chronobiology Disorders as they help synchronize their internal clock with the external environment, improving sleep quality and overall functioning.
Treatment of a patient with a circadian sleep-wake disorder using a combination of melatonin and metoprolol.

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
62 Previous Clinical Trials
19,130 Total Patients Enrolled

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT04652882 — Phase 3
Shift Work Sleep Disorder Research Study Groups: Tasimelteon, Placebo
Shift Work Sleep Disorder Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT04652882 — Phase 3
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT04652882 — Phase 3
Shift Work Sleep Disorder Patient Testimony for trial: Trial Name: NCT04652882 — Phase 3
~0 spots leftby Dec 2024